Press-release for stocks for NVSEF

symbols : NVSEF source : Www.globenewswire.com

save search

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| Email alert Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| Email alert Add to watchlist
malaria positive treatment for novartis

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Published: 2024-04-23 (Crawled : 18:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
lutathera fda first approved tumors for novartis therapy

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
MOR | News | $18.04 0.45% 0.44% 180K

Health Technology

| 0.39% | O: 0.39% H: 0.0% C: 0.0%
sales expansion novartis growth

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 6.51% | O: 0.87% H: 0.16% C: -0.59%
kesimpta sclerosis novartis show benefits

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K

Health Technology

| -0.84% | O: -1.94% H: 0.43% C: -0.34%
OCUL | News | $5.0 -1.48% -1.5% 2.3M

Health Technology

| -35.4% | O: -1.03% H: 3.66% C: 1.7%
ocular key leaders

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
fabhalta nephropathy for novartis show

Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| 2.02% | O: -0.32% H: 0.48% C: -0.17%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 4.54% | O: 0.32% H: 0.04% C: -0.56%
MOR | News | $18.04 0.45% 0.44% 180K

Health Technology

| 0.25% | O: 0.69% H: 0.0% C: -0.39%
for novartis

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| Email alert Add to watchlist
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| Email alert Add to watchlist
leqvio novartis therapy show

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $21.45 6.03% 5.91% 170K

n/a

| -4.26% | O: 6.23% H: 2.77% C: -10.21%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 2.57% | O: 0.47% H: 0.23% C: -0.99%
pharma business

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-28 (Crawled : 19:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| Email alert Add to watchlist
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| Email alert Add to watchlist
AVEO | $15.0 0.0% 0

Health Technology

| Email alert Add to watchlist
AUTL | $4.48 -1.75% -1.33% 1.7M

Health Technology

| Email alert Add to watchlist
medical

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| 0.33% | O: -100.0% H: NaN% C: Infinity%
ERAS | $1.93 4.32% 4.15% 440K

| -6.31% | O: 17.48% H: 6.94% C: -14.88%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 3.11% | O: 0.52% H: 0.0% C: 0.0%
LLY | News | $745.69 1.96% 0.04% 1.4M

Health Technology

| -5.03% | O: 0.28% H: 1.71% C: -0.3%
business year financial results

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| -0.4% | O: -100.0% H: NaN% C: Infinity%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 2.73% | O: -0.08% H: 0.15% C: -0.44%
AUTL | $4.48 -1.75% -1.33% 1.7M

Health Technology

| -29.11% | O: 2.53% H: 1.85% C: -2.31%
medical

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 2.89% | O: 0.17% H: 0.28% C: -0.01%
fabhalta first chmp positive novartis

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Published: 2024-03-20 (Crawled : 10:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| -0.93% | O: -1.37% H: 0.0% C: -1.58%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| 2.64% | O: -0.62% H: 0.45% C: 0.34%
BNTX | News | $88.49 0.55% 0.59% 330K

Health Technology

| -5.98% | O: -5.51% H: 1.33% C: 1.2%
management commercial

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Published: 2024-03-04 (Crawled : 07:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| -3.14% | O: -0.6% H: 0.68% C: 0.51%
children novartis

Genmab Publishes 2023 Annual Report
Published: 2024-02-14 (Crawled : 16:00) - globenewswire.com
GNMSF | News | $290.34 0.23% 3.83% 340

Health Technology

| 10.71% | O: 2.65% H: 4.56% C: 1.23%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| -0.2% | O: -0.02% H: 0.24% C: 0.01%
JNJ | News | $149.56 0.3% -0.17% 6.9M

Health Technology

| -5.1% | O: -0.91% H: 0.0% C: 0.0%
GMAB | News | $28.56 -1.42% -1.51% 530K

Health Technology

| 8.06% | O: 1.32% H: 5.34% C: 3.02%
report

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Published: 2024-02-05 (Crawled : 22:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K

Health Technology

| -7.47% | O: 0.72% H: 0.0% C: -1.56%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| -4.46% | O: -0.15% H: 0.6% C: 0.42%
MOR | News | $18.04 0.45% 0.44% 180K

Health Technology

| 4.46% | O: 1.39% H: 0.34% C: -7.08%
pipeline acquire novartis agreement

Mondelēz International Appoints Brian McNamara to Board of Directors
Published: 2024-02-02 (Crawled : 14:00) - globenewswire.com
HLNCF | $4.02 -2.66% -1.48% 200

n/a

| -3.37% | O: -2.64% H: 1.6% C: 1.48%
HLN | $8.41 0.6% 0.48% 2.9M

n/a

| 0.12% | O: -0.48% H: 0.0% C: -0.6%
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology

| -6.14% | O: -0.5% H: 0.26% C: -1.03%
MDLZ | $70.75 1.93% 1.91% 13M

Consumer Non-Durables

| -9.11% | O: 0.47% H: 0.38% C: -0.04%
international

Opthea Strengthens Team with Key Clinical and Regulatory Hires
Published: 2024-02-01 (Crawled : 11:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M

Health Technology